In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:Challenges with the pathologic testing for HER2-low expressionOptimal treatment of patients with HER2-low advanced breast cancerRole of TROP-2–targeted therapiesManagement of ADC-associated adverse events to optimize treatment outcomesADCs on the horizon for patients with advanced breast cancerPresenters:Sara M. Tolaney, MD, MPHChief, Division of Breast OncologyDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsMelinda Telli, MDProfessor of MedicineStanford University School of MedicineDirector, Breast Cancer ProgramStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.Link to full program:https://bit.ly/49WxRBM

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related